DRG payment reform has become the general trend, how should pharmaceutical companies deal with it?

[pharmaceutical network industry trends 】Some time ago, the state health insurance bureau, the Ministry of finance, the State Health Commission and the State Administration of traditional Chinese medicine jointly issued the notice on the list of pilot cities of countries paying by disease diagnosis related groups, which identified 30 cities such as Beijing, Tianjin and Handan city of Hebei Province as pilot cities of countries paying by disease diagnosis related groups (DRG), and required all pilot cities to ensure the 2020 simulation operation OK, the actual payment will be started in 2021 Recently, the National Health Insurance Bureau held the interpretation meeting of "technical specifications for DRG grouping and payment of national medical insurance" and "scheme for DRG grouping of national medical insurance (chs-drg)", officially announced the birth of CHS (China Healthcare Security) - DRGs and its technical specifications and grouping scheme, so as to promote the control of medical insurance expenses Because DRG is paid according to the fixed quota of each similar disease group, the hospital must consider its cost, and the use of drugs and consumables is more considered from the cost-benefit It may tend to reduce auxiliary drugs and use generic drugs with similar effect to high-cost original research drugs, so auxiliary drugs and high-cost original research drugs may be affected, and the significance of the original reference drug sales data of pharmaceutical companies will be greatly reduced, and the relevant pharmaceutical companies may be severely hit How should pharmaceutical companies deal with it? The author specially consulted the insiders, sorted out the following key points, and suggested that relevant enterprises should pay more attention to them Adjust product structure and increase innovation In recent years, with the restrictions on antibiotics, infusion and auxiliary drugs imposed by the state, its sales have been greatly affected For example, the sales proportion of traditional Chinese medicine (mainly affected by traditional Chinese medicine injection), infusion, auxiliary drugs and antibiotics in hospitals with more than 100 beds in the second quarter of 2019 has decreased by 3.9%, 1.3%, 4.9% and 1.1% respectively compared with Q2 in 2015, while the proportion of therapeutic drugs has increased 11.1% In order to control costs, the trend will be intensified after DRG is implemented Therefore, local pharmaceutical companies need to adjust product structure, abandon "non therapeutic drugs" and focus on the development and sales of therapeutic drugs Change the sales mode and sell by group DRG enables the sales of pharmaceutical companies to change from single product sales to a group of product sales This means that what drug companies need is not only the sales data of individual drugs, but also the possibility of product mix sales in a certain field for a certain disease group In particular, if we continue to carry out volume purchase in the future, most of the hospital's volume purchase data will be determined by medical insurance, which means that pharmaceutical companies need new ideas to deal with the sales change It is of great value for pharmaceutical enterprises to sell products in groups To improve the academic status of related products, the premise of DRG implementation is the establishment of clinical pathway and other standards Because the disease type attachment launched by the society of health economics only displays the category in the corresponding drug column, and there is no specific product common name Therefore, which variety to choose clinically is closely related to the current clinical pathway promoted by the state, and the choice of clinical pathway to the variety is closely related to the disease diagnosis and treatment guidelines and the evidence-based basis of the variety Whether to intervene in clinical pathway and guidance work in advance and form a favorable basis for academic status will become the focus of enterprise competition in the future Speed up the progress of consistency evaluation Under DRG payment mode, only the varieties that have passed the consistency evaluation have more opportunities to replace the original drugs with high prices, so pharmaceutical companies have to speed up the process of consistency evaluation In January 2019, 207 applications for consistency evaluation reached the peak After that, due to the excessive price reduction of 4 + 7, the enterprises hesitated for consistency evaluation, so the number of applications dropped sharply However, in view of the firm attitude to volume procurement, the enterprises accelerated the progress of consistency evaluation, and the number of applications in October has recovered to 97 Pay attention to pilot city reform and related varieties of academic promotion The national DRG collection and payment reform pilot city and hospital have coverage It is suggested that enterprises should understand the dynamics and development of DRG reform with their own terminal teams or commercial company teams, and adjust corresponding marketing strategies in understanding The grouping of DRG payment reform pilot cities is based on the previous clinical diagnosis and treatment methods, so high clinical acceptance is the main basis for selection, and increasing the product hospital coverage and quantity is an important basis for the sustainable growth of varieties in the future On the whole, DRG will make it more difficult for pharmaceutical companies to do business with hospitals Pharmaceutical companies that do not transform and do not layout in advance are very easy to be eliminated by the market.